The Anti-IL-17C Reference Antibody (MOR106) is a recombinant monoclonal antibody used as a reference standard in research, bioassays, and preclinical development for therapeutics targeting interleukin-17C (IL-17C), a pro-inflammatory cytokine involved in skin inflammation and immune responses. It is designed to mimic the binding and neutralizing properties of the therapeutic MOR106 antibody, facilitating studies on IL-17C-mediated pathways in conditions such as psoriasis and atopic dermatitis. By blocking IL-17C, it reduces inflammatory signals contributing to psoriatic lesions and other skin disorders. Clinical trials with the therapeutic counterpart have shown efficacy in moderate to severe plaque psoriasis, providing a targeted treatment with fewer systemic side effects than broad immunosuppressants. Research is also investigating applications in other IL-17C-driven chronic inflammatory and autoimmune diseases, including potential roles in rheumatoid arthritis and Crohn's disease.